Research program

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.
  • “Following our data presentation, we executed a follow-on equity offering of $150 million to bolster our balance sheet.
  • Cash Position and Runway: As of September 30, 2023, Alpine’s cash and investments totaled $227.2 million compared to $273.4 million as of December 31, 2022.
  • The respective increases of $0.8 million and $2.3 million were primarily attributable to increases in personnel and legal costs.

PREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM

Retrieved on: 
Monday, December 4, 2023

PreveCeutical has received direct interest in our diabetes & obesity dual gene therapy program from a world-leading pharmaceutical company established in the diabetes and obesity therapeutic space.

Key Points: 
  • PreveCeutical has received direct interest in our diabetes & obesity dual gene therapy program from a world-leading pharmaceutical company established in the diabetes and obesity therapeutic space.
  • To address the global rise of diabetes and obesity, and in furtherance of PreveCeutical's preventive health care focus, the Research Program builds on years of multi-disciplinary R&D in diabetes and obesity.
  • The rational design of tissue-targeted bioresponsive gene delivery systems (completed) will now be accompanied by gene- and protein-silencing in animal models of obesity and diabetes.
  • PreveCeutical has also approached multiple investment bankers and investors to provide the funding required to complete the preclinical studies.

BTQ and Hon Hai Research Institute Team Up To Help Pioneer Post-Quantum Cryptography Standards

Retrieved on: 
Wednesday, November 29, 2023

BTQ Technologies Corp. announces that its wholly owned subsidiary, BTQ AG, has entered into a Research and Collaboration Agreement with Hon Hai Research Institute.

Key Points: 
  • BTQ Technologies Corp. announces that its wholly owned subsidiary, BTQ AG, has entered into a Research and Collaboration Agreement with Hon Hai Research Institute.
  • In response to the call for PQC standard solicitation by the U.S. National Institute of Standards and Technology (NIST), BTQ and Hon Hai Research Institute's collaborative report was co-published in July 2023, demonstrating their combined expertise and commitment to advancing post-quantum cryptography standards.
  • The collaboration between BTQ and Hon Hai Research Institute began two years ago and the efforts in PQC led to the submission of a milestone report under the Research Program to the US National Institute of Standards and Technology (NIST) on June 1, 2023.
  • The contribution of Hon Hai Research Institute represents the forward-thinking direction in the field of post-quantum cryptography, which is in line with the trend of international academic research.

AMSilk appoints Gudrun Vogtentanz as Chief Scientific Officer

Retrieved on: 
Tuesday, October 17, 2023

MUNICH, Oct. 17, 2023 /PRNewswire/ -- AMSilk GmbH ("AMSilk"), the world's first industrial supplier of bio-based performance materials, today announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO).

Key Points: 
  • MUNICH, Oct. 17, 2023 /PRNewswire/ -- AMSilk GmbH ("AMSilk"), the world's first industrial supplier of bio-based performance materials, today announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO).
  • Ulrich Scherbel, Chief Executive Officer of AMSilk, said: "Gudrun's skills and experience in designing proteins and accelerating time-to-market are of significant importance for AMSilk in the current scale-up phase."
  • Gudrun Vogtentanz, Chief Scientific Officer of AMSilk, added: "AMSilk's protein-based products unlock the secrets of spider silk to create engineerable structures and solutions.
  • I am excited to join AMSilk, and look forward to making a difference in sustainability while simultaneously delivering high-performance products."

AMSilk appoints Gudrun Vogtentanz as Chief Scientific Officer

Retrieved on: 
Tuesday, October 17, 2023

MUNICH, Oct. 17, 2023 /PRNewswire/ -- AMSilk GmbH ("AMSilk"), the world's first industrial supplier of bio-based performance materials, today announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO).

Key Points: 
  • MUNICH, Oct. 17, 2023 /PRNewswire/ -- AMSilk GmbH ("AMSilk"), the world's first industrial supplier of bio-based performance materials, today announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO).
  • Ulrich Scherbel, Chief Executive Officer of AMSilk, said: "Gudrun's skills and experience in designing proteins and accelerating time-to-market are of significant importance for AMSilk in the current scale-up phase."
  • Gudrun Vogtentanz, Chief Scientific Officer of AMSilk, added: "AMSilk's protein-based products unlock the secrets of spider silk to create engineerable structures and solutions.
  • I am excited to join AMSilk, and look forward to making a difference in sustainability while simultaneously delivering high-performance products."

Briefing on Capitol Hill Urges More Government Action and Investment in the Epilepsies

Retrieved on: 
Wednesday, May 24, 2023

WASHINGTON, May 24, 2023 /PRNewswire/ -- In cooperation with the Congressional Epilepsy Caucus, organizations including the Epilepsy Foundation, Epilepsies Action Network, CURE Epilepsy, Rare Epilepsy Network and DEE-P Connections hosted a briefing on Capitol Hill on May 17 to educate about the epilepsies and call for more government action and investment in the epilepsies.

Key Points: 
  • WASHINGTON, May 24, 2023 /PRNewswire/ -- In cooperation with the Congressional Epilepsy Caucus, organizations including the Epilepsy Foundation, Epilepsies Action Network, CURE Epilepsy, Rare Epilepsy Network and DEE-P Connections hosted a briefing on Capitol Hill on May 17 to educate about the epilepsies and call for more government action and investment in the epilepsies.
  • (R-NC-3) and Jim Costa (D-CA-21) spoke about their personal connections to epilepsy and the importance of the caucus.
  • "My son developed epilepsy when he was 14 and it took us months to get the right treatment for him," said Congressman Murphy.
  • The annual total healthcare burden for people living with the epilepsies and/or seizures is at least $54 billion.

Lennox-Gastaut Syndrome (LGS) Foundation Hosts 8th Annual Walk 'n' Wheel for LGS Research

Retrieved on: 
Monday, May 1, 2023

SAN DIEGO, May 1, 2023 /PRNewswire/ -- On May 6, 2023, the Lennox-Gastaut Syndrome (LGS) Foundation will mobilize families, friends, and communities around the world to 'Step Towards the Cures, Together' at their 8th Annual Walk 'n' Wheel for LGS Research.

Key Points: 
  • SAN DIEGO, May 1, 2023 /PRNewswire/ -- On May 6, 2023, the Lennox-Gastaut Syndrome (LGS) Foundation will mobilize families, friends, and communities around the world to 'Step Towards the Cures, Together' at their 8th Annual Walk 'n' Wheel for LGS Research.
  • LGS is a rare, severe, life-threatening, epilepsy syndrome that develops in children and leads to lifelong disability.
  • The LGS Foundation is the only global organization dedicated to improving the lives of individuals and families impacted by LGS through advancing research, awareness, education, and family support.
  • A critical part of this Research Program is funding patient-led research by awarding Cure LGS 365 Research Grants.

Traction Uranium Hearty Bay Research Program Indicates Historical Exposure to Uranium Bearing Fluids in 3 Boreholes

Retrieved on: 
Wednesday, April 26, 2023

The main purpose of the Research Program is to assist the Company in determining whether there was uranium-bearing fluids within a target area and to help Traction’s team define and trace the conduit(s) of any such uranium-bearing fluids.

Key Points: 
  • The main purpose of the Research Program is to assist the Company in determining whether there was uranium-bearing fluids within a target area and to help Traction’s team define and trace the conduit(s) of any such uranium-bearing fluids.
  • Reference sample from the McArthur and Mann Lake uranium deposits was used as a comparative standard.
  • The main analytical techniques used for the Research Program are cathodoluminescence (“CL”) imaging and electron paramagnetic resonance (“EPR”) spectroscopy.
  • The separated quartz grains were pulverized into powders, which were checked for purity by powder X-ray diffraction (PXRD) analyses.

CRAACO®: Clinical Research as a Care Option Organized by the Conference Forum Announces Keynote and Key Topics for the 7th Annual Meeting

Retrieved on: 
Monday, March 6, 2023

NEW YORK, March 6, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced the launch of the 7th annual CRAACO®: Clinical Research as a Care Option conference, with the 2023 keynote and key topics. The meeting will take place May 22-23, 2023 at the Sheraton Imperial Hotel Raleigh-Durham Airport at Research Triangle Park, in Raleigh-Durham, NC.

Key Points: 
  • The Conference Forum announced the launch of the 7th annual CRAACO®: Clinical Research as a Care Option conference, May 22-23, 2023 in Raleigh-Durham, NC, with the 2023 keynote and key topics.
  • NEW YORK, March 6, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced the launch of the 7th annual CRAACO®: Clinical Research as a Care Option conference, with the 2023 keynote and key topics.
  • The meeting will take place May 22-23, 2023 at the Sheraton Imperial Hotel Raleigh-Durham Airport at Research Triangle Park, in Raleigh-Durham, NC.
  • "CRAACO is the only conference that examines how we can integrate care and research to give many more patients access to clinical research," said Valerie Bowling, Executive Director, Conference Forum.

Traction Uranium Provides Hearty Bay Research Program Update

Retrieved on: 
Tuesday, January 31, 2023

CALGARY, Alberta, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Traction Uranium Corp. (CSE: TRAC) (OTC: TRCTF) (FRA: Z1K) (the “Company” or “Traction”) is pleased to provide the following progress update on the Hearty Bay research program (the “Research Program”) currently being conducted by the Company’s research team on the Hearty Bay core samples collected from 14 diamond drill holes punched in the winter 2022 diamond drill program (see Traction’s previous news release dated August 30th, 2022).

Key Points: 
  • Research Project on the “radiation-induced defects in quartz” is a novel uranium vectoring technique pioneered by Dr. Yuanming Pan
    CALGARY, Alberta, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Traction Uranium Corp. (CSE: TRAC) (OTC: TRCTF) (FRA: Z1K) (the “Company” or “Traction”) is pleased to provide the following progress update on the Hearty Bay research program (the “Research Program”) currently being conducted by the Company’s research team on the Hearty Bay core samples collected from 14 diamond drill holes punched in the winter 2022 diamond drill program (see Traction’s previous news release dated August 30th, 2022).
  • The data from the work examines quartz degradation caused by radiation emitted from decaying uranium as another vector to add to the Company’s exploration program.
  • All selected core samples from the Hearty Bay Property (a total of 85 samples from 14 diamond drill holes) have been split into two halves.
  • The Research Program is a collaboration between the University of Saskatchewan and Traction, and aims to make use of radiation-induced defects in quartz as a new vector for uranium exploration at the Company’s Athabasca Basin properties.